A5078194079- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Antibiotic Use and Resistance
- Pharmaceutical industry and healthcare
- Healthcare Systems and Reforms
- Biosimilars and Bioanalytical Methods
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical studies and practices
- Global Health Care Issues
- Pharmaceutical Quality and Counterfeiting
- Antibiotic Resistance in Bacteria
- Medical History and Research
- Education, Healthcare and Sociology Research
- COVID-19 epidemiological studies
- Diverse Scientific and Economic Studies
- Urinary Tract Infections Management
- Fluorine in Organic Chemistry
- Frailty in Older Adults
- Economic and Financial Impacts of Cancer
- Medication Adherence and Compliance
- HIV/AIDS Impact and Responses
- Opioid Use Disorder Treatment
- Phosphodiesterase function and regulation
- Vaccine Coverage and Hesitancy
- Patient Satisfaction in Healthcare
Glostrup Hospital
2022
Hvidovre Hospital
2017-2022
World Health Organization Regional Office for Europe
2014-2020
Amager Hospital
2019
Imperial College London
2013
Roskilde Sygehus
2010
Introduction Surveillance of antimicrobial medicines consumption is central to improving their use and reducing resistance rates. There are few published data on antibiotic in Eastern Europe Central Asia. To address this, 18 non-European Union (EU) countries territories contribute the WHO Regional Office for (WHO Europe) Antimicrobial Medicines Consumption (AMC) Network. Objectives (i) Analyse 2015 J01 class antibacterials systemic from 16 AMC Network members; (ii) compare results with 2011...
Early market entry and rapid uptake of quality assured generic biosimilars are key to improving access medicines, say Alessandra Ferrario colleagues
Achieving FAir Pricing oF MedicinesDefining the concept of fair pricing for medicines Suerie Moon and colleagues consider what makes a price both buyers sellers H igh rising prices have attracted public concern from poorest to richest countries.For example, 1500 patient groups surveyed in 78 countries, only 9% believed that pharmaceutical companies were "excellent or good" at having "fair policies".This figure has hovered between 11% 15% since survey began 2011. 1 Politicians, experts,...
The 3-day course on the managed introduction of new drugs was organised by Piperska group together with Agency for Health Technology Assessment and Tariff System (AOTMiT) WHO Europe to share experiences case histories among health authority insurance company personnel, academics those from commercial organisations across potential ways optimise entry medicines.This starts pre-launch horizon scanning budgeting, then peri-launch including critical drug evaluation, finally post launch...
Universal Health Coverage is key to reach the overall health-related Sustainable Development Goal, and within this, access safe, effective, quality, affordable essential medicines critical. Currently, for noncommunicable diseases in many countries are not available when needed if they present, unaffordable. Countries face challenges of rising prevalence due increasing risk factors ageing populations, along with under-diagnosis under-treatment. Providing disease only one piece a complex...
Quality indicators are increasingly used as a tool to achieve safe and quality clinical care, cost-effective therapy, for professional learning, remuneration, accreditation financial incentives. A substantial number focus on drug therapy but few address the introduction of new medicines even though this is burning issue. The objective was describe issues challenges in designing implementing transparent indicator framework evaluation protocol provide guidance how apply managed entry...
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease diagnosed prevalence of 2.0%. Fortunately, it now curable in most patients. Sales medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by launch protease inhibitors (PIs) boceprevir (BCV) telaprevir (TVR) addition ribavirin pegylated interferon (pegIFN). Costs will continue rise new treatments including sofosbuvir, which include free regimens. Objective: Assess uptake...
In October 2015, the third international Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference was held in Vienna to foster discussion on challenges pricing reimbursement policies for medicines. The research presented highlighted that commonly used pharmaceutical are not sufficiently effective address current challenges. participants called fundamental reforms ensure access medicines, particularly new potentially more and/or safe while safeguarding financial sustainability...
Introduction:The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain -its principal indication.The threatened legal action in the UK if generic rather than Lyrica is prescribed this indication.No problems exist practitioners who prescribe epilepsy or generalized anxiety disorder.This serious implications health authorities.In Germany, however, historically generics can be legally any approved indication once one loses its patent.Aim: To establish...
An issue of growing concern for health policy-makers in Europe is the continuing rise spending on pharmaceuticals. In OECD countries pharmaceutical expenditure rose by 3.5% per year between 2000 and 2009, averages 18-19% total [1]. Similar are seen across Europe, with representing largest component ambulatory care [2]. Spending some has dropped since 2009 account specific policy decisions taken due to financial crisis, but others this growth remained constant [1,3]. Contributing continual...
Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed perceived growth OOP outpatient medicines, including those covered by the benefits package scheme (the Additional Drug Package, ADP). The study aimed explore extent of co-payments ADP-listed medicines explain reasons developments.
This meeting was held from the 30 October to 1 November 2018 in Almaty, Kazakhstan. The brought together participants 16 countries of central Asia, Caucasus, eastern Europe and expert speakers western India. Participants discussed analysis use data on antimicrobial medicines consumption, country experiences enforcing legislation for prescription-only access antibiotics, role primary health care (PHC) tackling resistance (AMR), strategies improving competencies practitioners using...